Shugan Jiangzhuo Tablets mitigate non-alcoholic fatty liver disease by modulating TLR4/MyD88/NF-κB signaling pathway through gut microbiota - PubMed
8 hours ago
- #NAFLD treatment
- #TLR4 signaling
- #gut microbiota
- Shugan Jiangzhuo Tablets (SGJZ) effectively improve NAFLD symptoms like body weight, lipid metabolism, and liver pathology in a zebrafish model.
- SGJZ modulates the gut microbiota, increases beneficial bacteria such as Cetobacterium, and strengthens the intestinal barrier to reduce inflammation.
- The therapeutic effects of SGJZ are linked to inhibition of the TLR4/MyD88/NF-κB signaling pathway in the liver, and these benefits diminish in pseudo-germ-free zebrafish.